Cardiac Biotech Solutions - CBSC

01/15/2026

Cardiac Biotech Solutions, Inc. (OTCID: CBSC) has activated its China manufacturing and regulatory pathway for the MyCardia AT cardiac event monitoring platform.

Through its partnership with Ebulent Medical (Shenzhen) Ltd., an NMPA-licensed medical device manufacturer, the Company has initiated regulated manufacturing preparation, production line setup, and required hospital field trials. These activities support the final regulatory submission process for commercial clearance in China.

This development follows recent international milestones, including regulatory approval in Canada and exclusive distribution agreements in Central and South America. Together, these steps reflect CBSC’s methodical approach to global commercialization, leveraging established regulatory infrastructure and region-specific distribution partnerships.

The MyCardia AT platform combines wearable cardiac monitoring with cloud-based connectivity and mobile applications, supporting a recurring revenue model aligned with regional healthcare economics.

The Company will provide additional updates as regulatory and commercialization milestones are completed.

Learn More: https://cardiacbiotech.com/cardiac-biotech-solutions-activates-china-production-pipeline-for-mycardia-at-and-moves-into-final-nmpa-submission-phase/

Cardiac Biotech Solutions (CBSC) activates China manufacturing with Ebulent Medical and enters final NMPA submission phase for MyCardia AT.

09/25/2025

Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT

Cardiac Biotech Solutions, Inc., today announced that its MyCardia AT device has been issued a Medical Device License (MDL) by Health Canada and is now approved for import into Canada, effective immediately. The device, rebranded as the CardioHolter AT, will be tested and distributed through CBSC’s manufacturing partner, Nasiff Associates, located in Central Square, NY. Nasiff Associates is a Health Canada-licensed establishment operating under a certified ISO 13485 Quality Management System (QMS) that complies with Health Canada standards for Class II medical devices.

CBSC’s exclusive Canadian distributor, Your Heart Protector Corp. (Calgary, Alberta), has placed an initial order for CardioHolter AT devices totaling $375,000 USD. Delivery of the first 1,000 devices will occur upon completion of production (currently underway), with the balance scheduled for shipment within 90–120 days.

In addition to revenue from device sales, CBSC has implemented a monthly rental program that provides recurring income whenever devices are deployed in hospitals and healthcare facilities. The program fees include access to the device, the AWS Cloud-based monitoring platform, and patient-facing mobile applications. Revenue from these usage fees is shared between CBSC and its distributor partners, with pricing tailored to each country’s healthcare economics and reimbursement environment.

“With Canada’s vast geography and many remote communities, there is a critical need for flexible, easy-to-use monitoring solutions that extend beyond major metropolitan areas,” said Charles Martin, Chief Executive Officer of CBSC. “The CardioHolter AT is designed to meet that need. Whether using standard landline telephone connections or newer cellular and WiFi-enabled technologies, patients can reliably transmit recorded ECG data to their physicians for timely review and diagnosis. This technology empowers physicians to achieve better patient outcomes, improved diagnoses, and enhanced quality of life regardless of a patient’s location.”

“Our company is proud to have received licensing approval from Health Canada for the CardioHolter AT device, and we look forward to launching our services in Canada,” said Elmer N. Johnson, co-owner of Your Heart Protector Corp. “We are excited to help bring this innovative device to the Canadian market, as it represents a significant advancement in remote monitoring that will provide physicians greater ability to detect, diagnose, and treat irregular heart rhythms earlier, ultimately leading to better patient outcomes.”

The Company continues to advance the global commercialization of its MyCardia AT cardiac event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the United States and Canada, and an additional submission progressing in China, CBSC’s mission is to deliver state-of-the-art cardiac monitoring solutions worldwide.

Learn More: https://cardiacbiotech.com/cardiac-biotech-solutions-inc-secures-health-canada-license-for-mycardia-at-device-now-branded-as-cardioholter-at/

Cardiac Biotech Solutions (CBSC) secures Health Canada license for CardioHolter AT, with a $375K order from Your Heart Protector Corp in Canada.

09/11/2025

CBSC Announces $375,000 Purchase Order and Launch of Recurring Revenue Program with Noventis Medical

Cardiac Biotech Solutions, Inc., today announced the receipt of an initial purchase order from Noventis Medical, its exclusive Central America distribution partner, for the supply of 2,500 MyCardia AT Cardiac Event Monitoring devices. The total order value is $375,000 USD based on a per-unit price of $150.

Under the terms of the agreement, 1,000 devices will be shipped immediately upon completion of production, with the remaining 1,500 units to be delivered within 90 days.

“This purchase order not only reinforces market demand for the MyCardia AT but also marks the beginning of a sustainable, long-term revenue model,” said Charles Martin, Chief Executive Officer of CBSC. “By combining device sales with recurring software-driven rental fees, we believe that we are positioned to deliver consistent value for both our healthcare partners and our shareholders.”

In addition to upfront device sales, CBSC has implemented a recurring monthly rental program to generate ongoing revenue from devices once deployed in hospitals and healthcare facilities. This program covers the use of each device, the AWS Cloud-based monitoring software, and patient-facing smartphone applications.

Revenue from the monthly rental program is shared between CBSC and its distributor partners, with CBSC receiving one-third of the monthly fee and the distributor retaining the balance. Pricing varies by country, reflecting regional healthcare economics and reimbursement practices.

The Company continues to advance the global commercialization of its MyCardia AT cardiac event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the United States and additional submissions progressing in Canada and China, this newest international agreement represents another significant milestone in CBSC’s mission to deliver state-of-the-art cardiac monitoring solutions worldwide.

More here: https://cardiacbiotech.com/cbsc-announces-375000-purchase-order-and-launch-of-recurring-revenue-program-with-noventis-medical/

Cardiac Biotech Solutions (CBSC) announces $375K purchase order with Noventis Medical and launches recurring revenue program for MyCardia AT devices.

09/04/2025

Cardiac Biotech Solutions, Inc. (CBSC) today announced the ex*****on of a new distribution agreement with Noventis Medical, granting the Company five-year exclusive rights to distribute CBSC’s products across Costa Rica, Panama, Colombia, and Argentina.

Under the terms of the agreement, Noventis Medical has committed to a total of $600,000 USD contract value for the distribution rights. In addition, the Company has granted Noventis a right of first refusal for any future distribution opportunities across other Central and South American countries, provided it can match the terms offered by other prospective partners.

“We are delighted to expand our international presence through this new strategic partnership with Noventis Medical,” said Charles Martin, Chief Executive Officer of CBSC. “This agreement strengthens our reach into key Latin American markets and, we believe, provides a solid foundation for additional regional expansion. We also believe that the right of first refusal provision also ensures that our long-term collaboration with Noventis can grow in step with future opportunities across Central and South America.”

John Quam, President of Noventis Medical stated, “Noventis Medical is very excited to collaborate with CBSC and its product, MyCardia AT, to bring a reliable solution for identifying heart issues in the Latin American market. Cardiovascular disease remains the leading cause of death in the region, and this technology provides doctors with early insights so they can address problems and keep patients healthier for longer. We are committed to working alongside the medical community to deliver innovative tools that truly make a difference.”

Learn More: https://cardiacbiotech.com/cardiac-biotech-solutions-inc-cbsc-signs-exclusive-5-year-distribution-agreement-with-noventis-medical-covering-costa-rica-panama-colombia-and-argentina/

05/08/2025

We’re proud to announce our official corporate name change to Cardiac Biotech Solutions, Inc. (OTC PINK: CBSC).

This change reflects our commitment to advancing precision-driven, non-invasive cardiac monitoring technologies. With FDA clearance for the MyCardia AT event monitor and distribution partners secured across Southeast Asia, Hong Kong, Macau, and Canada, we’re poised to expand access to next-generation remote cardiac care.

Our device, platform, and mobile apps integrate seamlessly with the AWS Cloud, providing a cohesive experience across iOS, Android, and WeChat for patients and providers alike.

We are building the future of ambulatory cardiac diagnostics—smart, scalable, and globally accessible.

🔗 Learn more: https://cardiacbiotech.com/cb-scientific-inc-cbsc-announces-corporate-name-change-to-cardiac-biotech-solutions-inc/

CBSC is now Cardiac Biotech Solutions, reflecting a global focus on FDA-cleared, cloud-connected cardiac monitoring technology.

02/25/2025

CB Scientific Inc. (CBSC) launches the next-gen MyCardia AT cardiac monitor! This FDA-cleared device is lightweight, wearable, and transmits event recordings via iOS & Android apps. 📲

Now in the process of regulatory approvals for future distribution in SE Asia, Hong Kong, and Macau! 🌏 Early detection of cardiac arrhythmias can help reduce heart disease risks & improve patient outcomes.



CB Scientific Inc. (CBSC) Formally Launches Next Generation MyCardia AT Cardiac Monitor

LAS VEGAS, NV / ACCESSWIRE / February 25, 2025 / CB Scientific, Inc. (OTC PINK:CBSC) (“CBSC” or the “Company”), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products, announced today that the Company, in partnership with its contract manufacturer Datrix, LLC, is launching its next generation MyCardia AT cardiac event monitor targeted for use with our international distribution network in SE Asia, Hong Kong, and Macau. The newly branded MyCardia AT device is FDA-cleared and is designed to provide an improved patient remote cardiac monitoring experience with its lightweight, easy-to-wear design, including flexible and convenient options to transmit event recordings over an iOS or Android smartphone and utilizing our MyCardia Apple, Google or WeChat app.

The MyCardia AT cardiac event monitor helps physicians detect, identify, and diagnose potential cardiac arrhythmias in patients with intermittent transient symptoms closer to the time that they occur up to a 30-day monitoring period. Early detection and treatment of cardiac rhythm disorders helps to significantly reduce the burden of cardiac disease which can damage the heart and may even lead to an increased risk of stroke and death. According to the World Health Organization, since 2000 the largest increase in deaths is from ischemic heart disease which multiplied from 2.7 million to 9.1 million, and in 2021 accounted for 13% of the world’s total deaths. The MyCardia AT device can also be used as an in-office ECG screening device.

The Company is strategically enhancing its remote cardiac monitoring portfolio with the launch of the MyCardia AT device. This initiative aims to leverage the strength of our established brand name to drive recognition, streamline our product ecosystem, and reinforce our market presence. The MyCardia AT marketing strategy involves seamlessly integrating with our existing AWS Cloud-based MyCardia portal and the widely adopted MyCardia iOS and Android smartphone applications, with the goal of ensuring a cohesive and optimized user experience on a global scale.

Our established distributors in Malaysia, Singapore, Thailand, Indonesia, Hong Kong, and Macau will now begin registering the MyCardia AT device with their respective regulatory agencies for import approval. Upon completion, the MyCardia AT device will begin shipping at that time and be widely available throughout these respective markets going forward. Additionally next step regulatory submission work will immediately resume for the MyCardia AT towards the approval of our representative Chinese manufacturing partner Shenzhen Pump. The Company will also continue working directly with representatives from the National Medical Products Administration (NMPA) in China towards the completion of clearance to market approval for our device into that market. Regulatory submission will also begin with our Canadian distributor Your Heart Protector Corp. towards clearance to market acceptance throughout Canada.

As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.

About CB Scientific, Inc.

CB Scientific, Inc., through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our electrocardiogram (EKG) devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

Company Contact Information:

Telephone: (888) 225-0870
Email: General Inquiries: [email protected]
Investor Inquiries: [email protected]
Follow CBSC: X, Facebook, Instagram, LinkedIn, YouTube, and Newsletter

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE:

CBSC launches the FDA-cleared MyCardia AT cardiac event monitor for enhanced remote heart monitoring, now rolling out in SE Asia, Hong Kong, and Macau.

10/04/2024

appoints William "Trip" Thomas as Chief Financial Officer, effective Oct 1, 2024.



https://cbscientificinc.com/trip-thomas-appointed-as-chief-financial-officer/

08/20/2024

We're voluntarily delisting its common stock (“Common Stock”) from trading on the OTCQB Venture Market. Delisting from the OTCQB Venture Market will have no impact on Company’s Common Shares which will continue to trade on the OTC Pink Open Market providing stockholders the ability to trade their shares in the public market as they can do now.

The decision to delist from the OTCQB Venture Market was made to preserve capital for implementing the company’s business plan. As the Company achieves certain milestones, and when conditions are appropriate, it will be prepared to re-engage an auditor and apply to uplist.

Voluntary delisting from the OTCQB to preserve capital for business plan. The shares will continue to trade publicly on the OTC Pink Open Market.

03/19/2024

CB Scientific, Inc. - CBSC announces a successful Annual Meeting of Stockholders, with over 66% voting support. Shareholders back name change to Cardiac Biotech Solutions, Inc., pending regulatory approval. CEO, Charles Martin, highlights shareholder confidence & future growth plans.

Shareholders endorse name change to Cardiac Biotech Solutions, Inc. subject to regulatory approval

04/28/2023

As the population ages, demand for ambulatory devices is expected to surge. should consider companies like CB Scientific, Inc. - CBSC, which are well-positioned to capitalize on this growing market. https://yhoo.it/3oVi6Z1

Major players in the cardiac arrhythmia monitoring devices market are AliveCor Inc., Biotronik, GE Healthcare, iRhythm Technologies Inc., Koninklijke Philips N.V., Medtronic plc, Nihon Kohden Corporation, Smart Solutions Technologies S.New York, April 26, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com an...

04/06/2023

Investors take note: the ambulatory cardiac monitoring devices market is set to explode, according to Grand View Research. This trend bodes well for companies like that specialize in this area.

The global ambulatory cardiac monitoring devices market size was valued at USD 5.77 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 10.4% over the forecast period from 2023 to 2030

03/09/2023

Your Heart Protector Corp. to market the Company’s products and provide associated monitoring services throughout Canada

Las Vegas, NV / ACCESSWIRE / March 9, 2023 / CB Scientific. Inc. (OTCQB:CBSC) (“CBSC” or the “Company”), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products and services, today announced that it has finalized a comprehensive distribution agreement with newly formed Your Heart Protector Corp. based in Okotoks, Alberta, Canada. The exclusive, renewable 5-year contract provides for conducting marketing and distribution of products, as well as all associated monitoring services, all of which are expected to launch later this year.

“As with our other international distributors, the initial start-up process for Your Heart Protector Corp. involves our development of localized cloud-based acquisition software, customization of the associated iOS and Android smartphone apps, as well as assistance in facilitating the requisite regulatory approval for the myCam 1.1 product through the Medical Devices Directorate (MDD) in Canada,” said Charles Martin, Chief Executive Officer of CB Scientific, Inc. “Based on completion of each of the various distributor onboarding tasks, and as soon as MDD clearance is granted, Your Heart Protector Corp. will be fully prepared to commence sales and marketing activities throughout Canada.”

As previously announced, CBSC tendered a 510(k) “Clearance to Market” submission for its myCam 1.1 device to the U.S. Food and Drug Administration (FDA) early last fall and has consistently collaborated with the agency in a resolute manner to obtain timely Clearance to Market for the product. Upon FDA clearance, the company plans to commence marketing the device domestically, as well as continuing with its intent to market the device throughout a number of offshore markets where it has already established local business relationships.

Read here: https://bit.ly/3J19CGd